Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study

Go back to Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1123.91 -25.45 (2.21%)
Previous Close $1149.36    52 Week High $88.16 
Open $1133.00    52 Week Low $67.88 
Day High $1134.53    P/E 260.16 
Day Low $1113.55    EPS $4.32 
Volume 2,402,850